Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

Pfizer logo in blue

News

What Pfizer's Upgrade Means For Mutual Fund Investors (PFE)

Shauna O'Brien Mar 23, 2015



Inside the Upgrade


The firm has raised its 2015 EPS estimates from $2.07 to $2.08. FY2016 EPS estimates were increased from $2.21 to $2.30.

The analyst commented: “We expect PFE shares to significantly appreciate over the next 1-2 years based on a better than expected launch of Ibrance, greater appreciation of the durable growth on offer in GEP, further accretive and potentially tax-driven M&A, and the separation of GEP by 2017 at a minimum from the rest of the business.”


Growth and Income


The stock has grown at a steady rate over the last few years and has a dividend yield of about 3.2%. Pfizer stock is perhaps most ideal for income-focused investors that are planning on holding the stock over the long-haul.


Mutual Funds to Watch



The Bottom Line


If you’ve enjoyed this article, sign up for the free MutualFunds.com newsletter; we’ll send you similar content weekly.

Download Our Free Report

Why 30 trillion is invested in mutual funds book